Semaglutide

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist available as Ozempic (injection, type 2 diabetes), Wegovy (injection, chronic weight management), and Rybelsus (oral tablet, type 2 diabetes). All three formulations share the same generic name, semaglutide, and are manufactured by Novo Nordisk.

How It Works

Semaglutide mimics a naturally occurring hormone called GLP-1 that is released from the gut after eating. According to the FDA-approved prescribing information, semaglutide works through three main pathways. First, it stimulates the pancreas to release insulin only when blood sugar is elevated, reducing the risk of low blood sugar compared to some other diabetes drugs. Second, it signals the pancreas to release less glucagon — a hormone that raises blood sugar — after meals. Third, it acts on receptors in the brain that regulate appetite and food intake, which slows the rate at which the stomach empties (gastric emptying). This slower emptying is responsible for many of the gastrointestinal side effects, particularly early in treatment, and also contributes to feelings of fullness after smaller meals. Semaglutide has a half-life of approximately one week, which is why it is dosed once weekly in its injectable forms.

Side Effects by Week

The timeline below is derived from adverse event reporting across the SUSTAIN and STEP clinical trial programs and reflects the dose-escalation schedule described in FDA labeling. Individual experiences will vary.

Most Common Side Effects

The following adverse reactions were reported at ≥5% incidence in placebo-controlled trials and are listed in the FDA-approved prescribing information for Ozempic and Wegovy.

• Nausea: The most frequently reported side effect, occurring in up to 44% of Wegovy-treated patients in the STEP 1 trial (Wilding et al., NEJM 2021), compared to 16% on placebo; it typically peaks within the first four weeks.
• Diarrhea: Reported in approximately 30% of Wegovy patients in STEP 1, versus 16% on placebo, and generally occurs in the first weeks of treatment or after dose escalation.
• Vomiting: Occurred in 24% of Wegovy-treated participants in STEP 1 compared to 6% on placebo, and is the most common reason for early discontinuation per FDA labeling.
• Constipation: Reported in 24% of Wegovy patients in STEP 1 versus 11% on placebo; tends to become more prominent during the maintenance phase than the titration phase.
• Abdominal pain: Described in FDA labeling as occurring at the higher maintenance doses and includes cramping, bloating, and general abdominal discomfort.
• Headache: Reported in approximately 14% of Wegovy-treated patients in STEP 1, an adverse event believed to be related to reduced caloric intake and fluid shifts rather than a direct drug effect.
• Fatigue: Listed in FDA labeling and observed across STEP trials; most common during the first four to eight weeks of treatment.
• Dyspepsia (indigestion): Reported in the SUSTAIN trial program for Ozempic; related to slowed gastric emptying and may include bloating and upper abdominal discomfort after meals.
• Injection-site reactions: Redness, bruising, or mild itching at the injection site were reported in less than 1% of patients in Ozempic trials per FDA labeling; rotating injection sites reduces incidence.
• Hypoglycemia (low blood sugar): Rare when semaglutide is used as monotherapy, but the FDA label warns of increased risk when combined with sulfonylureas or insulin.

Serious Side Effects

The following serious adverse events are described in the Warnings and Precautions section or Boxed Warning of FDA-approved semaglutide prescribing information.

• ⚠️ Thyroid C-cell tumors (Boxed Warning): Semaglutide caused thyroid C-cell tumors in rodent studies at clinically relevant exposures; FDA labeling states it is unknown whether semaglutide causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans. Semaglutide is contraindicated in patients with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
• ⚠️ Acute pancreatitis: Cases of fatal and non-fatal pancreatitis have been reported in patients treated with GLP-1 receptor agonists per FDA labeling; patients should be observed for signs of pancreatitis (severe, persistent abdominal pain radiating to the back) and semaglutide should be discontinued if pancreatitis is suspected.
• ⚠️ Acute gallbladder disease: Cholelithiasis (gallstones) and cholecystitis were reported more frequently with Wegovy than placebo in STEP trials; the STEP 1 trial reported serious gallbladder events in 2.6% of the semaglutide group versus 1.2% on placebo (Wilding et al., NEJM 2021).
• ⚠️ Hypoglycemia with concomitant agents: Severe hypoglycemia requiring medical assistance was reported in SUSTAIN trials when semaglutide was combined with insulin or sulfonylureas; FDA labeling recommends dose reduction of these concomitant agents.
• ⚠️ Acute kidney injury: Post-marketing cases of acute kidney injury, sometimes requiring dialysis, have been reported, primarily in patients who experienced severe nausea, vomiting, and dehydration; reported in FDA labeling under Warnings and Precautions.
• ⚠️ Diabetic retinopathy complications: In the SUSTAIN 6 cardiovascular outcomes trial (Marso et al., NEJM 2016), diabetic retinopathy complications occurred in 3.0% of semaglutide-treated patients versus 1.8% on placebo; FDA labeling for Ozempic includes this warning for patients with a history of diabetic retinopathy.
• ⚠️ Heart rate increase: Mean increases of 1–4 beats per minute in resting heart rate were observed with semaglutide across clinical programs per FDA labeling; clinical significance of this sustained increase is uncertain, and monitoring is recommended in patients with known cardiac conditions.
• ⚠️ Suicidal ideation: FDA issued a notice in 2023 that it is evaluating reports of suicidal thoughts in patients using GLP-1 receptor agonists including semaglutide; as of the 2023 label revision, FDA concluded data did not support a causal relationship but monitoring remains advisable.
• ⚠️ Hypersensitivity reactions: Serious hypersensitivity reactions including anaphylaxis and angioedema have been reported post-marketing and are listed in FDA labeling; semaglutide should be discontinued immediately if such reactions occur.

Managing Side Effects

Nausea

Nausea is the most reported reason for early discontinuation of semaglutide, per FDA labeling. The FDA-approved dose escalation schedule — starting at 0.25 mg (injectable) or 3 mg (oral) for four weeks before increasing — exists specifically to improve gastrointestinal tolerability. Strategies supported by clinical practice include eating smaller meals, avoiding high-fat or spicy foods, not lying down within two to three hours of eating, and staying well hydrated. The STEP trials did not formally evaluate anti-nausea medications, but prescribers may consider short-term use of agents such as ondansetron for severe cases.

Vomiting

Vomiting was the single most common adverse event leading to discontinuation in STEP 1 (Wilding et al., NEJM 2021). If vomiting prevents adequate fluid intake for more than 24 hours, dehydration and secondary acute kidney injury become risks per FDA labeling. Patients should contact their prescriber or seek medical attention if they cannot keep fluids down. Dose reduction or a prolonged titration schedule may be considered by a prescriber in cases of intolerable vomiting, as FDA labeling permits a flexible escalation timeline.

Constipation

Constipation reflects slowed intestinal motility from GLP-1 receptor activation. FDA labeling identifies constipation as a common adverse reaction at all semaglutide doses. Adequate fluid intake (water, not sugary beverages), gradual increases in dietary fiber, and physical activity may help. Over-the-counter osmotic laxatives (e.g., polyethylene glycol) are commonly used in clinical practice, though this was not formally studied in the STEP trials.

Diarrhea

Diarrhea in semaglutide users is typically mild to moderate and self-limiting per FDA labeling and STEP trial adverse event data. Maintaining hydration is the primary concern. Patients should avoid dehydration, which can trigger kidney complications noted in FDA post-marketing surveillance. If diarrhea persists beyond two weeks at a given dose, prescribers should assess whether dose escalation should be paused.

Injection-Site Reactions

FDA labeling for Ozempic and Wegovy recommends rotating injection sites among the abdomen, upper thigh, and upper arm with each weekly dose. Allowing the pen to reach room temperature before injecting and avoiding areas of active skin irritation can reduce local reactions. Injection-site nodules, bruising, or redness that persist beyond 72 hours should be reported to a healthcare provider.

Hair Thinning

Hair thinning (telogen effluvium) was reported in approximately 3% of Wegovy-treated patients in STEP 1 versus less than 1% on placebo. This is a well-characterized response to rapid caloric restriction and weight loss rather than a direct drug toxicity. Per published STEP trial data, episodes are typically temporary and resolve within six months without a change in medication. Adequate dietary protein intake (sufficient to preserve lean body mass) is a common clinical recommendation.

Cost and Access in 2026

Frequently Asked Questions

This page is for informational purposes only and does not constitute medical advice. Consult your prescriber before making any medication decisions.